Tel Aviv, July 22, 2025 - SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification from The Nasdaq Stock Market LLC on July 18, 2025, confirming that its ordinary shares maintained a closing bid price of at least $1.00 for 10 consecutive business days. This compliance resolves the prior bid price deficiency issue, and Nasdaq now considers the matter closed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.